𝔖 Bobbio Scriptorium

✦ LIBER ✦

15 The rationale of pelvic lymphadenectomy in patients with Stage Ib cancer of the cervix: a diagnostic or therapeutic procedure?

✍ Scribed by Kjorstad, Kjell E.

Book ID: 122614817
Publisher: Elsevier Science
Year: 1988
Tongue: English
Weight: 490 KB
Volume: 2
Category: Article
ISSN: 0950-3552
DOI: 10.1016/S0950-3552(98)80017-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized Trial of Pelvic Radiation T

A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study

✍ Alexander Sedlis; Brian N. Bundy; Marvin Z. Rotman; Samuel S. Lentz; Laila I. Mu 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Is pelvic radiation beneficial in the po

Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy?: A report from the presidential panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists

✍ C.Paul Morrow; Hugh M. Shingleton; J.Max Austin; Hervy E. Averette; Robert E. Gi 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 286 KB

The diagnostic accuracy of CT and MRI in

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

✍ A.M. Hövels; R.A.M. Heesakkers; E.M. Adang; G.J. Jager; S. Strum; Y.L. Hoogeveen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Treatment of (“bulky”) stage IB cervical

Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group

✍ Gary L. Eddy; Brian N. Bundy; William T. Creasman; Nick M. Spirtos; Robert S. Ma 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 272 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB

Treatment Rationale and Study Design for

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 100 KB